智飞生物(300122) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 30,652,415,906.61, representing a 101.79% increase compared to CNY 15,190,366,231.21 in 2020[13]. - The net profit attributable to shareholders for 2021 was CNY 10,208,548,452.56, a 209.23% increase from CNY 3,301,326,830.15 in 2020[13]. - The basic earnings per share for 2021 was CNY 6.3803, up 209.23% from CNY 2.0633 in 2020[13]. - The total assets at the end of 2021 amounted to CNY 30,047,323,465.36, a 97.48% increase from CNY 15,215,241,753.29 at the end of 2020[13]. - The company reported a weighted average return on equity of 78.01% for 2021, an increase of 31.72% compared to 46.29% in 2020[13]. - The total revenue for 2021 reached approximately CNY 30.65 billion, representing a year-on-year increase of 101.79% from CNY 15.19 billion in 2020[56]. - Revenue from self-developed products amounted to CNY 9.70 billion, accounting for 31.64% of total revenue, with a remarkable growth of 707.61% compared to CNY 1.20 billion in 2020[56]. - The company reported a significant increase in sales volume, reaching 284,180,087 doses in 2021, up 864.95% from 29,450,087 doses in 2020[59]. - The company achieved a revenue of CNY 30,652,415,906.61 in 2021, representing a growth of 101.79% compared to the previous year[29]. Dividend Distribution - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares to all shareholders, based on a total of 1,600,000,000 shares[2]. - The company implemented a cash dividend policy, distributing 6.00 CNY per 10 shares, totaling 960 million CNY in cash dividends, which accounted for 100% of the total profit distribution[137]. - The company reported a total distributable profit of 12,291,924,179.08 CNY for the year 2021[137]. Research and Development - The company invested CNY 814 million in research and development during the reporting period[31]. - The company is investing heavily in R&D, with a budget allocation of 200 million RMB for the development of new vaccines and biopharmaceuticals[111]. - The company aims to enhance its vaccine research and development technology platform, targeting market potential and commercial development prospects[80]. - The company has multiple products in clinical trials, including three entering Phase III trials and two entering Phase I trials[30]. - The company has established three major R&D and production bases to accelerate the development and registration of high-quality products[42]. - The company has a strong pipeline of vaccines, including several in advanced clinical trial stages for various infectious diseases[32]. - The company has 11 products on the market, including vaccines for meningitis, cervical cancer, pneumonia, and rotavirus, addressing various infectious diseases[24]. Market Strategy and Operations - The company emphasizes a dual-driven development model of "technology + market" to support its growth strategy[23]. - The company operates under a "sales-driven production" model, aligning production with market demand[28]. - The company has established a professional marketing team of nearly 3,000 members, covering all 31 provinces and municipalities in China, and over 30,000 grassroots health service points[49]. - The company has a sales team of 2,817 members, which supports its operational plans but also presents management challenges[87]. - The company is actively pursuing WHO certification for its COVID-19 vaccine to improve accessibility and affordability, contributing to global immunization efforts[38]. - The company is focused on enhancing its brand influence and product competitiveness both domestically and internationally[85]. Compliance and Governance - The company emphasizes compliance and quality management, adhering to various laws and regulations to ensure sustainable operations[37]. - The company has a robust governance structure, with independent operational capabilities and no competition with its controlling shareholder[103]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations[100]. - The company has established a performance evaluation and incentive mechanism that aligns with its development status[97]. - The company published 4 periodic reports and 64 temporary reports during the reporting period, enhancing information transparency[97]. Environmental Compliance - The company is classified as a key pollutant discharge unit, indicating compliance with environmental regulations[148]. - The total chemical oxygen demand (COD) discharge was 7.7896 tons, with a concentration of 56.0 mg/L, well below the permitted limit[148]. - The company has implemented measures to ensure no significant defects in non-financial reporting[147]. - The company reported a significant reduction in emissions, with sulfur dioxide levels at <3 mg/Nm³ and nitrogen oxides at 28 mg/Nm³, adhering to the relevant environmental standards[151]. - The company has completed the low-nitrogen combustion transformation of two boilers, further reducing nitrogen oxide emissions[154]. Shareholder Information - The total shares held by the board members at the beginning of the period were 904,121,300, with a decrease of 4,691,000 shares during the period, resulting in an ending total of 899,430,300 shares[106]. - The largest shareholder, Jiang Rensheng, holds 50.11% of the shares, totaling 801,829,000, with a decrease of 3,691,000 shares during the reporting period[183]. - The number of shareholders holding ordinary shares at the end of the reporting period was 111,593, an increase from 89,963 at the end of the previous month[183]. - The company introduced strategic investors through share transfers to optimize its equity structure and reduce operational risks[180]. Employee Engagement and Development - The company emphasizes employee training and development, focusing on various training programs to enhance employee capabilities and align with business goals[133]. - The employee stock ownership plan involved 761 core employees holding a total of 16,150,000 shares, representing approximately 1.01% of the company's total equity[138]. - The company has a diverse workforce, with 1,137 production staff, 2,817 sales personnel, and 566 technical staff[131]. - The company has a total of 491 employees with master's degrees and 6 with doctoral degrees, indicating a strong educational background among its workforce[131]. Future Outlook - The company plans to expand its production capacity by 40% in the next two years to meet growing demand for its vaccines[158]. - The company aims to achieve carbon neutrality by 2030, implementing various green initiatives across its operations[159]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in innovative biotechnologies[111]. - Future outlook includes plans to expand into international markets, targeting a 15% increase in overseas sales by the end of the next fiscal year[111].